ZA202001027B - Vasopressin receptor antagonists and products and methods related thereto - Google Patents
Vasopressin receptor antagonists and products and methods related theretoInfo
- Publication number
- ZA202001027B ZA202001027B ZA2020/01027A ZA202001027A ZA202001027B ZA 202001027 B ZA202001027 B ZA 202001027B ZA 2020/01027 A ZA2020/01027 A ZA 2020/01027A ZA 202001027 A ZA202001027 A ZA 202001027A ZA 202001027 B ZA202001027 B ZA 202001027B
- Authority
- ZA
- South Africa
- Prior art keywords
- products
- receptor antagonists
- methods related
- vasopressin receptor
- vasopressin
- Prior art date
Links
- 239000002536 vasopressin receptor antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554452P | 2017-09-05 | 2017-09-05 | |
| PCT/US2018/049607 WO2019050988A1 (en) | 2017-09-05 | 2018-09-05 | ANTAGONISTS OF THE VASOPRESSIN RECEPTOR, PRODUCTS AND RELATED METHODS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202001027B true ZA202001027B (en) | 2023-10-25 |
Family
ID=63708454
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/01027A ZA202001027B (en) | 2017-09-05 | 2020-02-18 | Vasopressin receptor antagonists and products and methods related thereto |
| ZA2021/04313A ZA202104313B (en) | 2017-09-05 | 2021-06-23 | Vasopressin receptor antagonists and products and methods related thereto |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/04313A ZA202104313B (en) | 2017-09-05 | 2021-06-23 | Vasopressin receptor antagonists and products and methods related thereto |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10538530B2 (https=) |
| EP (1) | EP3679043B9 (https=) |
| JP (1) | JP7368357B2 (https=) |
| KR (1) | KR102765806B1 (https=) |
| CN (1) | CN111212842B (https=) |
| AU (1) | AU2018330423B2 (https=) |
| CA (1) | CA3072766A1 (https=) |
| ES (1) | ES2951874T3 (https=) |
| IL (1) | IL272563B2 (https=) |
| MX (1) | MX2020002436A (https=) |
| SG (1) | SG11202001498QA (https=) |
| WO (1) | WO2019050988A1 (https=) |
| ZA (2) | ZA202001027B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106810536A (zh) | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
| CN117295726A (zh) * | 2021-04-23 | 2023-12-26 | 豪夫迈·罗氏有限公司 | 杂环化合物 |
| WO2023130050A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US20250170100A1 (en) * | 2021-12-29 | 2025-05-29 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment of anxiety and related conditions |
| CN120379996A (zh) * | 2022-08-11 | 2025-07-25 | 瑞敏德股份有限公司 | 用于治疗神经退行性障碍的(氮杂)螺庚烷衍生物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2025005A (en) * | 1930-01-02 | 1935-12-17 | Union Switch & Signal Co | Multiple control apparatus |
| DE3930262A1 (de) * | 1989-09-11 | 1991-03-21 | Thomae Gmbh Dr K | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5091387A (en) * | 1990-03-02 | 1992-02-25 | Merck & Co., Inc. | Spirocyclic oxytocin antagonists |
| HUP0203548A3 (en) * | 1999-07-21 | 2003-04-28 | Astrazeneca Ab | New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use |
| WO2006034015A1 (en) * | 2004-09-17 | 2006-03-30 | Osi Pharmaceuticals, Inc. | (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors |
| KR100984893B1 (ko) * | 2005-07-21 | 2010-10-01 | 에프. 호프만-라 로슈 아게 | Ｖ1ａ 수용체 길항제로서의인돌-3-일-카보닐-피페리딘-벤조이미다졸 유도체 |
| US7351706B2 (en) * | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| JP2010504352A (ja) * | 2006-09-22 | 2010-02-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | バソプレッシン拮抗薬としてのスピロベンズアゼピン類 |
| DE602007006990D1 (de) | 2006-12-07 | 2010-07-15 | Hoffmann La Roche | Spiropiperidinderivate als antagonisten des via-rezeptors |
| DE602007006989D1 (en) * | 2006-12-07 | 2010-07-15 | Hoffmann La Roche | Spiropiperidinderivate |
| US8329904B2 (en) | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| WO2011036204A1 (en) * | 2009-09-24 | 2011-03-31 | Shire-Movetis N.V. | [1,4]-benzodiazepines as vasopressin v2 receptor antagonists |
| CN105263910A (zh) | 2013-02-18 | 2016-01-20 | 斯克利普斯研究所 | 具有治疗潜力的血管加压素受体调节剂 |
| JP6502267B2 (ja) | 2013-02-18 | 2019-04-17 | スプリング バンク ファーマシューティカルズ，インコーポレイテッド | ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計 |
| US9688678B2 (en) * | 2014-05-15 | 2017-06-27 | AbbVie Deutschland GmbH & Co. KG | Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases |
| US9527856B2 (en) * | 2014-05-15 | 2016-12-27 | AbbVie Deutschland GmbH & Co. KG | Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases |
| WO2018226769A1 (en) * | 2017-06-05 | 2018-12-13 | Blackthorn Therapeutics, Inc. | 1-(2-azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives as v1a receptor antagonists for treating neuropsychological disorders |
| WO2020123872A1 (en) | 2018-12-12 | 2020-06-18 | Blackthorn Therapeutics, Inc. | 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders |
-
2018
- 2018-09-05 EP EP18779495.3A patent/EP3679043B9/en active Active
- 2018-09-05 CN CN201880057828.7A patent/CN111212842B/zh active Active
- 2018-09-05 ES ES18779495T patent/ES2951874T3/es active Active
- 2018-09-05 MX MX2020002436A patent/MX2020002436A/es unknown
- 2018-09-05 KR KR1020207009443A patent/KR102765806B1/ko active Active
- 2018-09-05 CA CA3072766A patent/CA3072766A1/en active Pending
- 2018-09-05 AU AU2018330423A patent/AU2018330423B2/en active Active
- 2018-09-05 SG SG11202001498QA patent/SG11202001498QA/en unknown
- 2018-09-05 US US16/122,780 patent/US10538530B2/en active Active
- 2018-09-05 JP JP2020534818A patent/JP7368357B2/ja active Active
- 2018-09-05 WO PCT/US2018/049607 patent/WO2019050988A1/en not_active Ceased
-
2020
- 2020-02-09 IL IL272563A patent/IL272563B2/en unknown
- 2020-02-18 ZA ZA2020/01027A patent/ZA202001027B/en unknown
-
2021
- 2021-03-05 US US17/194,069 patent/US12152038B2/en active Active
- 2021-06-23 ZA ZA2021/04313A patent/ZA202104313B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2951874T3 (es) | 2023-10-25 |
| US12152038B2 (en) | 2024-11-26 |
| IL272563A (en) | 2020-03-31 |
| EP3679043B1 (en) | 2023-05-31 |
| ZA202104313B (en) | 2024-12-18 |
| IL272563B2 (en) | 2023-02-01 |
| IL272563B (en) | 2022-10-01 |
| EP3679043B9 (en) | 2023-09-27 |
| WO2019050988A1 (en) | 2019-03-14 |
| AU2018330423A1 (en) | 2020-03-05 |
| CN111212842B (zh) | 2022-10-25 |
| CN111212842A (zh) | 2020-05-29 |
| EP3679043A1 (en) | 2020-07-15 |
| KR102765806B1 (ko) | 2025-02-10 |
| KR20200051686A (ko) | 2020-05-13 |
| US20190169202A1 (en) | 2019-06-06 |
| US20210317126A1 (en) | 2021-10-14 |
| US10538530B2 (en) | 2020-01-21 |
| AU2018330423B2 (en) | 2023-04-06 |
| JP2020532592A (ja) | 2020-11-12 |
| JP7368357B2 (ja) | 2023-10-24 |
| MX2020002436A (es) | 2020-07-13 |
| NZ762031A (en) | 2024-04-26 |
| CA3072766A1 (en) | 2019-03-14 |
| SG11202001498QA (en) | 2020-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906107B (en) | Kappa opioid receptor antagonists and products and methods related thereto | |
| ZA202104313B (en) | Vasopressin receptor antagonists and products and methods related thereto | |
| IL269574A (en) | Aryl hydrocarbon receptor antagonist and its uses | |
| IL249373A0 (en) | Polypeptide formulations of related detector and method | |
| IL266472A (en) | Indazole derivatives as alpha-v-integrin antagonists | |
| IL292692B1 (en) | Mrgprx2 antagonists and their uses | |
| IL274883A (en) | BRADYKININ B2 receptor antagonists | |
| ZA202101406B (en) | Integrin antagonists | |
| GB201702617D0 (en) | Receptor | |
| IL267686A (en) | Integrin antagonists | |
| IL274751A (en) | ILDR2 antagonists and combinations thereof | |
| SG11202002207QA (en) | Trpv2 antagonists | |
| GB201815629D0 (en) | Antagonists | |
| GB201519194D0 (en) | CGRP receptor antagonists | |
| GB201702174D0 (en) | Orexin receptor antagonists | |
| GB201707499D0 (en) | Orexin receptor antagonists | |
| PT3613739T (pt) | Antagonistas de integrina | |
| SG11202105784WA (en) | Antagonists | |
| ZA201807767B (en) | Angiotensin-1-receptor antagonists | |
| GB201707504D0 (en) | Orexin receptor antagonists | |
| PT3464324T (pt) | Antagonistas de recetores da angiotensina-1 | |
| GB201701887D0 (en) | Receptor | |
| GB201700926D0 (en) | Receptor |